Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GALR3 | O60755 | 2/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9302509 | 0.91 | PTAFR (0.83) | PTAFRHRH3TNFGALR3NR2F2 | |
| SCHEMBL9302693 | 0.89 | PTAFR (0.80) | PTAFRHRH3ALDH1A1KDM4EMEN1 | |
| SCHEMBL9301338 | 0.88 | PTAFR (0.78) | PTAFRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9303630 | 0.87 | PTAFR (0.77) | PTAFRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9302507 | 0.87 | PTAFR (0.77) | PTAFRHRH3ALDH1A1KDM4EMEN1 | |
| SCHEMBL9303479 | 0.87 | PTAFR (0.76) | PTAFRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9304261 | 0.86 | PTAFR (0.75) | PTAFRHRH3ALDH1A1KDM4EMEN1 | |
| SCHEMBL9302097 | 0.84 | PTAFR (0.72) | PTAFRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9303746 | 0.80 | PTAFR (0.67) | PTAFRHRH3ALDH1A1TNFKDM4E | |
| SCHEMBL9302023 | 0.79 | PTAFR (0.66) | PTAFRHRH3ALDH1A1TNFGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1990009997-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1990-09-07 | — | — | WO | claimed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025075089-A1 | BIARYL COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE | 住友化学株式会社 | 2025-04-10 | — | — | WO | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. | 2024-08-22 | — | — | US | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| EP-4223755-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION INCLUDING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116456817-A | Heterocyclic compound and harmful arthropod control composition containing same | 住友化学株式会社 | 2023-07-18 | — | — | CN | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| EP-3911716-B1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2022-09-21 | — | — | EP | disclosed |
| CN-114436942-A | Arylamine compound containing carbazole group and organic electroluminescent device thereof | 长春海谱润斯科技股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022071428-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION INCLUDING SAME | 住友化学株式会社 | 2022-04-07 | — | — | WO | disclosed |
| US-5314880-A | Platelet activating factor antagonist | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-05-24 | — | — | US | disclosed |
| EP-0468971-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| WO-1990009997-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | PTAFR 3847/4885HRH3 988/4885ALDH1A1 1338/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | PTAFR 1775/4885HRH3 2629/4885ALDH1A1 525/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | PTAFR 1775/4885HRH3 2629/4885ALDH1A1 525/4885 |
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | SOS1, HRAS, KRAS | PTAFR 3093/4885HRH3 3334/4885ALDH1A1 4139/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | PTAFR 1775/4885HRH3 2629/4885ALDH1A1 525/4885 |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | PTAFR 2774/4885HRH3 3469/4885ALDH1A1 4355/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | PTAFR 1775/4885HRH3 2629/4885ALDH1A1 525/4885 |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | PTAFR 2740/4885HRH3 3475/4885ALDH1A1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.